The strong growth of biosimilars Pfizer recently launched in the United States are part of the success story, although reference etanercept (Enbrel) sales have seen major erosion.
Third-quarter earnings for Pfizer revealed a strong upward pattern for biosimilar penetration, despite the coronavirus disease 2019 (COVID-19).
Biosimilar revenues climbed to $424 million (up 80%), driven mainly by the recent launches of biosimilars for rituximab (Ruxience), bevacizumab (Zirabev), and trastuzumab (Trazimera) products in the United States and elsewhere, Pfizer said in an earnings report.
The company also cited ongoing growth in revenues from its epoetin zeta biosimilar (Retacrit), mainly in the United States.
Pfizer said sales declined 21% overall for its reference product Enbrel (etanercept) owing to competition in Europe, Japan, and Brazil, where biosimilars of this drug are available.
Biosimilar and generic competition for Pfizer’s products that are losing or have lost patent protection was cited for an anticipated “negative revenue impact of $2.4 billion” for the full year 2020. However, success with Pfizer’s own biosimilar launches contributed to 4% overall operational revenue growth, the company said. Third-quarter revenues totaled $12.1 billion.
“In the first 9 months of the year, our biopharma business grew 7% operationally, despite a COVID-19–related negative impact of approximately 2%, driven by the strong performance of many of our key brands,” said Frank D’Amelio, chief financial officer and executive vice president of Global Supply for Pfizer.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.